Peptide library

5-Amino-1MQ is a small synthetic molecule, not a peptide, that blocks the enzyme NNMT. It is sold beside peptides, mostly as 50 mg oral capsules and sometimes as injectable vials. In obese mice it cut body weight and fat without changing food intake. No human trial exists, so every human dose you see is community or guide practice, and oral and injected doses sit on very different scales.

Adamax is a nootropic peptide sold as a longer-lasting Semax. Its developer describes it as Semax with an acetyl cap on the front and an adamantane group on the back, and has said it launched with no research of any kind. We found no human study, no animal study and no pharmacokinetic data. Two versions circulate, about 984 Da without adamantane and about 1032 Da with it, and some buyers report lab tests showing plain N-acetyl Semax. Every dose on this page is a vendor suggestion or a user report.

AOD-9604 is a 16 amino acid fragment of the tail end of human growth hormone, built to keep GH's fat-burning signal without its growth effects. It was developed as an oral obesity drug, and its biggest trial failed to beat placebo. Today people inject it under the skin, usually next to a GLP-1, at doses no trial ever tested. It is not FDA approved, has no lawful 503A compounding route, and is banned in sport.

A synthetic 15 amino acid peptide (GEPPPGKPADDAGLV, about 1,419 Da) based on a fragment of a protein in human gastric juice. People run it for tendons, muscles, joints and the gut. The animal data run deep. The human data are three tiny uncontrolled reports, with real trials only now registered. Not approved anywhere.

BPC-157 and TB-500 in one vial at 1:1: a 10 mg vial holds 5 mg of each, a 20 mg vial 10 mg of each. It is the best-known healing stack. The catch is the fixed ratio: BPC-157 is usually dosed daily and TB-500 in big weekly loads, so one vial cannot copy both schedules. No human trial has tested the pair at these doses.

Cagrilintide is a long-acting, lab-made version of amylin, the fullness hormone your pancreas releases with insulin after meals. Novo Nordisk added a fatty-acid chain so one shot lasts about a week. It hits a different receptor family from GLP-1 drugs, so most people use it as an add-on to semaglutide, tirzepatide or retatrutide. Paired with semaglutide it is CagriSema, which has phase 3 data and a pending FDA filing. Cagrilintide on its own is not approved anywhere.

CJC-1295 is a lab-made GHRH analog that tells the pituitary to release more growth hormone. It comes in two very different forms. With DAC it binds to albumin and works for about a week. Without DAC (Mod GRF 1-29) it clears in hours and gives a short pulse. Labels often say 'CJC-1295' for the no-DAC product, so check which one you have before you dose.

The most popular GH peptide pairing. CJC-1295 without DAC (Mod GRF 1-29) amplifies the growth hormone pulse, and ipamorelin triggers it. It comes as two vials or one pre-mixed vial. The common 10 mg blend holds 5 mg of each, not 10 mg of each. No human trial has tested this pair, so every dose here is a guide or community convention.

DSIP is a 9-amino-acid peptide found in 1977 in the blood of sleeping rabbits and named for deep, slow-wave sleep. People inject 100 to 300 mcg before bed hoping to fall asleep faster and sleep deeper. The catch: no receptor has ever been found, the human trials are small 1980s IV studies with mixed results, and plenty of users on r/Peptides report it did nothing or kept them awake. It is not FDA approved, and an FDA panel voted against allowing it in compounding in July 2026.

Epitalon is a synthetic four amino acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a Russian pineal gland extract. People take it for longevity and telomeres, but sleep is what they report most. Guides run 5 to 10 mg a day for 10 to 20 days, a figure that traces to the extract. The human epitalon studies used 0.01 to 0.5 mg. Not FDA approved.

A three amino acid peptide (glycine, histidine, lysine) bound to copper. Your body makes it: plasma levels run about 200 ng/mL at 20 and 80 ng/mL by 60. People use it for skin, hair and healing, on the skin or by injection. The human evidence is all topical. Injection has none, and the injected dose varies 10 to 30 fold between guides.

GHRP-2 and GHRP-6 are two six-amino-acid peptides that switch on the ghrelin (hunger hormone) receptor. That fires a GH pulse and, to different degrees, raises appetite, cortisol and prolactin. GHRP-2 gives more GH per mcg with milder hunger. GHRP-6 brings strong hunger, which is why bulkers like it. GHRP-2 is a licensed diagnostic drug in Japan; neither is approved in the US.

One vial holding GHK-Cu, BPC-157 and TB-500 at 5:1:1, 70 mg in total. GHK-Cu is about 71% of every draw, so this is a copper-peptide product with repair peptides riding along. It is a seller formulation, not a tested drug, and the name GLOW is also used loosely for copper-peptide skincare.

IGF-1 LR3 is a lab-made version of IGF-1, the hormone GH tells your liver to make. Two changes keep it from sticking to the binding proteins that normally park IGF-1, so more of it is free to act. It was built as a cell-culture reagent, not a drug, and has never been tested in a human study. Bodybuilders run it at 20 to 40 mcg a day, with carbs.

Ipamorelin is a five-amino-acid peptide that triggers a short burst of your own growth hormone. It is a GH secretagogue, not GH. People like it because, in the animal work that defined it, it released GH without the cortisol bump other GHRPs cause. Human data are short IV studies only, so the doses people run come from guides and community convention.

One 80 mg vial holding four peptides at 5:1:1:1: GHK-Cu 50 mg plus BPC-157, TB-500 and KPV at 10 mg each. GHK-Cu is 62.5% of every draw. KLOW is a seller formulation name, not a compound, and nobody has studied it. The biggest dosing risk is the water: five competitors call four different volumes standard.

The last three amino acids (lysine, proline, valine; about 342 Da) of alpha-MSH. It is studied as an anti-inflammatory, mainly for the gut. It does not tan you. No human trial has tested it at any dose by any route. The animal data are oral, yet most guides lead with injection.

A 16 amino acid peptide the body makes from a gene inside mitochondria. In mice it acts like an exercise signal for metabolism, and blood levels rise with exercise in people. Users run it for fat loss, energy and longevity, often next to a GLP-1 or SS-31. Nobody has measured a human dose or half-life. The first real trial started in 2026. It is banned in sport.

NAD+ is the coenzyme every cell burns to make energy and run repair enzymes. It is not a peptide, but it is sold like one: powder in a vial, mixed and injected. Home users inject 25 to 100 mg under the skin a few times a week; clinics drip 250 to 1,000 mg by IV. Swallowed NAD+ barely absorbs. No controlled human trial has set a subQ dose, and the IV data is small and rough on tolerability.

PT-141, or bremelanotide, is a 7-amino-acid peptide that turns up sexual desire through melanocortin receptors in the brain. It is FDA approved as Vyleesi, a 1.75 mg shot women take at least 45 minutes before sex, no more than once a day and 8 times a month. Men use it off label at 1 to 3 mg, often with Cialis. The trade-off is nausea: 40% got it in the phase 3 trials. Frequent dosing also darkens skin.

Retatrutide is a once-weekly injected peptide from Lilly that hits three receptors at once: GLP-1, GIP and glucagon. That makes it the first triple agonist in late trials. Phase 3 results put average weight loss in the high 20s percent at the top dose. It is not approved yet, so everything outside a trial is grey market.

A seven amino acid peptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) built on tuftsin, a small immune peptide, with the same Pro-Gly-Pro tail as Semax. Russia sells it over the counter as 0.15% nasal drops for anxiety. People use it for anxiety, social nerves, a racing mind at night, and to take the edge off Semax. Human data are a few small Russian trials. Not approved in the US.

Semaglutide is a once-weekly GLP-1 receptor agonist from Novo Nordisk, a modified gut hormone built to last about a week in the blood. It is FDA approved as Ozempic, Rybelsus and Ozempic tablets for type 2 diabetes and as Wegovy for weight, heart risk and MASH, in weekly shots, daily tablets and a 7.2 mg high dose. Many people instead use compounded pharmacy vials or research-labeled powder, which have no trial data of their own. In STEP 1, 2.4 mg weekly averaged about 15% weight loss, and about two-thirds of it came back within a year of stopping.

A seven amino acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) made from a short piece of ACTH, with a Pro-Gly-Pro tail added for stability. Its label says it has none of ACTH's hormone activity. Russia registers it as 0.1% and 1% nasal drops for stroke recovery and brain function. People run it for focus and drive, by nose or injection. Human data are small Russian studies, mostly in stroke. Not approved in the US.

Sermorelin is the first 29 amino acids of your body's own GHRH, the shortest piece that still works. It tells the pituitary to release growth hormone in its normal pulses. It was once an FDA-approved drug (Geref) for children with GH deficiency, then pulled from the market for commercial reasons, not safety. Today it is a clinic and self-use staple at 200 to 300 mcg before bed.

A tiny four amino acid peptide that sticks to cardiolipin inside mitochondria. As elamipretide (Forzinity) it is the only longevity peptide here with an FDA approval, for Barth syndrome only. Trials use 40 mg a day; most users run 0.5 to 10 mg for energy, endurance and longevity. Fatigue is the most-posted complaint. Research vials are not the approved drug.

In the analytical and anti-doping literature, TB-500 is Ac-LKKTETQ: a 7 amino acid fragment (residues 17 to 23, about 889 Da) of the 43 amino acid protein thymosin beta-4. What ships in a vial labelled TB-500 varies. People run it for soft-tissue recovery, usually with BPC-157, on a loading then maintenance schedule. Every human trial used the full protein, not the fragment.

Tesamorelin is the only GHRH analog with current FDA approval. It makes your pituitary release more of your own growth hormone, which raises IGF-1. In Phase 3 trials it cut visceral belly fat by about 15% in adults with HIV-related fat gain. That approval and that data are why it stands apart from every other GH peptide. Off label, people run it for belly fat and recomposition.

Tirzepatide is a once-weekly injectable peptide from Lilly that hits two gut-hormone receptors, GIP and GLP-1. It is FDA approved as Mounjaro for type 2 diabetes and as Zepbound for weight management and sleep apnea with obesity. In SURMOUNT-1, people on 15 mg lost about 21% of body weight. Outside the label, people run compounded or research vials, slow titrations, microdoses and split doses. Those off-label patterns have no trials behind them. Online sellers often call it "GLP-2", which is a nickname for second generation, not a different drug.